PCI Synthesis Announces Successful FDA inspection and Pre-Approval of Two Products

September 23, 2013

Brings the company's total to eight active pharmaceutical ingredients (APIs) to receive Pre-Approval/Commercial status

Newburyport, MA – PCI Synthesis, Inc. (www.pcisynthesis.com), a custom chemical manufacturer of new chemical entities (NCE), generic active pharmaceutical ingredients (API), and other specialty chemical products, announced the completion of the sixth inspection of the company’s cGMP site in Newburyport, MA by the FDA.

During the multi-week inspection, the FDA conducted a general cGMP compliance review as well as Pre-Approval Inspections (PAIs) for two active pharmaceutical ingredients (APIs) filed by two different clients earlier this year. PCI now has a total of eight products that have been successfully Pre-Approved and/or commercialized to date.

PCI, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as active pharmaceutical ingredients (APIs), currently has four new chemical entities in clinical development that were recently included in the "Top 50 Drugs in Development to Watch" list. In addition, over the past two years, PCI has launched more than five new proprietary APIs for the generic market with exclusive supply agreements – bringing its total to 17 exclusive APIs in its overall pipeline.

"Everyone at PCI is continuously working to improve the quality systems throughout our organization. Our efforts and investments in our facilities, training and new technologies, have been validated by another successful FDA inspection. More than that, the latest PAI pre-approvals further substantiate that our team understands the complex dynamics of small molecule development, including manufacturing, process optimization, scale up and comprehensive analytical support," said Edward S. Price, President of PCI Synthesis. "The focus on product approvals and approved APIs is part of our commitment to full scale R&D, which further positions PCI as an innovative CMO.”

About PCI Synthesis

PCI Synthesis is a 15-year-old custom chemical manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products. A contract manufacturing organization (CMO), PCI provides small and mid-sized companies with expertise needed to manufacture complex small molecules to be used in both the branded and generic market.



Membership Deliverables

MassBio Membership gives you:

Purchasing power-MassBio negotiates a broad-based collection of services on behalf of member companies and passes the savings on to its members. 

Networking and professional development-MassBio organizes and executes numerous conferences, committee meetings, and networking events throughout the year.

MassBio Signature Events-Attend our Investors Forum, Innovator Roundtables, Pharma Days, our Golf Classic Fundraiser, Policy Leadership Breakfast, and many others.

Public policy & Advocacy-As the state's leading advocate for our life science super cluster, we fight for public policy initiatives and tax incentives in Massachusetts and Washington, D.C., that will enable biotechnology companies to do their best work.

Economic development-MassBio provides expert advice and guidance to help companies find suitable locations and resources as they move to and grow in the Bay State. We make Massachusetts a better place for your business.

Visibility/Resources-Members are listed on a searchable directory that includes a profile and link to the company's website. We highlight your company's latest news by posting to our MassBio member news page. In addition, members can post job openings on our website free!

Educational incentives-We promote education, workforce development and lifelong learning through the MassBioEd Foundation. The foundation customizes training programs for companies and educational institutions and promotes science in the classroom through BioTeach. MassBio members receive a discount on courses offered by the foundation.